These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

136 related items for PubMed ID: 23151430

  • 21. Re: The effects of combined androgen blockade on cognitive function during the first cycle of intermittent androgen suppression in patients with prostate cancer.
    Gardiner RA, Nicol DL, Green HJ, Yaxley J, Watson R, Mactaggart P, Headley BC, Swanson C, Pakenham KI.
    J Urol; 2004 Aug; 172(2):774; author reply 774-5. PubMed ID: 15247782
    [No Abstract] [Full Text] [Related]

  • 22. Re: The use of zoledronic acid in men receiving androgen deprivation therapy for prostate cancer with severe osteopenia or osteoporosis.
    Griebling TL.
    J Urol; 2011 Apr; 185(4):1279. PubMed ID: 22098960
    [No Abstract] [Full Text] [Related]

  • 23. Serum markers as a predictor of response duration and patient survival after hormonal therapy for metastatic carcinoma of the prostate.
    Smith JA, Lange PH, Janknegt RA, Abbou CC, deGery A.
    J Urol; 1997 Apr; 157(4):1329-34. PubMed ID: 9120932
    [Abstract] [Full Text] [Related]

  • 24. Prostate volume reduction with androgen deprivation therapy before interstitial brachytherapy.
    Kucway R, Vicini F, Huang R, Stromberg J, Gonzalez J, Martinez A.
    J Urol; 2002 Jun; 167(6):2443-7. PubMed ID: 11992054
    [Abstract] [Full Text] [Related]

  • 25. Maximal androgen blockade in prostatic cancer.
    Denis L.
    Scand J Urol Nephrol Suppl; 1991 Jun; 138():137-44. PubMed ID: 1838427
    [No Abstract] [Full Text] [Related]

  • 26. Bisphosphonates effective in preventing bone complications associated with androgen deprivation therapy.
    J Support Oncol; 2006 Feb; 4(2):99-100. PubMed ID: 16499137
    [No Abstract] [Full Text] [Related]

  • 27. Combination treatment versus LHRH alone in advanced prostatic cancer.
    Ferrari P, Castagnetti G, Ferrari G, Baisi B, Dotti A.
    Urol Int; 1996 Feb; 56 Suppl 1():13-7. PubMed ID: 8776812
    [Abstract] [Full Text] [Related]

  • 28. [Tolerance and clinical and biological responses during the first 6 months of treatment with 1-month sustained release LHRH agonists leuprolerin and triptolerin in patients with metastatic prostate cancer].
    Abbou CC, Lucas C, Leblanc V.
    Prog Urol; 1997 Dec; 7(6):984-95. PubMed ID: 9490144
    [Abstract] [Full Text] [Related]

  • 29. Bicalutamide alone prior to brachytherapy achieves cytoreduction that is similar to luteinizing hormone-releasing hormone analogues with less patient-reported morbidity.
    Petit JH, Gluck C, Kiger WS, Henry DL, Karasiewicz C, Talcott J, Berg S, Holupka E, Kaplan I.
    Urol Oncol; 2008 Dec; 26(4):372-7. PubMed ID: 18367113
    [Abstract] [Full Text] [Related]

  • 30. Case records of the Massachusetts General Hospital. Case 16-2011. A 67-year-old man with recurrent prostate cancer.
    Smith MR, Zietman AL, Finkelstein JS, Wu CL.
    N Engl J Med; 2011 May 26; 364(21):2044-51. PubMed ID: 21612474
    [No Abstract] [Full Text] [Related]

  • 31. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    De Luca A, Normanno N.
    N Engl J Med; 2009 May 28; 360(22):2368-9; author reply 2369-70. PubMed ID: 19484815
    [No Abstract] [Full Text] [Related]

  • 32. Endocrine therapy plus zoledronic acid in premenopausal breast cancer.
    Berruti A, Buttigliero C, Dogliotti L.
    N Engl J Med; 2009 May 28; 360(22):2368; author reply 2369-70. PubMed ID: 19484817
    [No Abstract] [Full Text] [Related]

  • 33. Gonadotropin releasing hormone analogue antiandrogen failure secondary to a pituitary adenoma.
    Ogan K, Berger M, Ball R.
    J Urol; 1998 Aug 28; 160(2):497-8. PubMed ID: 9679910
    [No Abstract] [Full Text] [Related]

  • 34. Lifestyle factors and duration of androgen deprivation affect bone mineral density of patients with prostate cancer during first year of therapy.
    Ryan CW, Huo D, Stallings JW, Davis RL, Beer TM, McWhorter LT.
    Urology; 2007 Jul 28; 70(1):122-6. PubMed ID: 17656221
    [Abstract] [Full Text] [Related]

  • 35. [Loss of bone mass in patients with prostate cancer subjected to androgenic deprivation].
    Morote J, Planas J.
    Actas Urol Esp; 2011 Apr 28; 35(4):232-9. PubMed ID: 21419516
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Explaining objective responses to zoledronic acid.
    Sorscher SM.
    Anticancer Drugs; 2012 Nov 28; 23(10):1121. PubMed ID: 23023113
    [No Abstract] [Full Text] [Related]

  • 39. Radical prostatectomy and adjuvant endocrine therapy for prostate cancer with or without preoperative androgen deprivation: Five-year results.
    Homma Y, Akaza H, Okada K, Yokoyama M, Moriyama N, Usami M, Hirao Y, Tsushima T, Sakamoto A, Ohashi Y, Aso Y, Prostate Cancer Study Group.
    Int J Urol; 2004 May 28; 11(5):295-303. PubMed ID: 15147545
    [Abstract] [Full Text] [Related]

  • 40. The moving landscape of locally advanced prostate cancer: combination of external irradiation and endocrine treatment and/or multimodal approach.
    Bolla M.
    Eur Urol; 2012 Aug 28; 62(2):220-1; author reply 222-3. PubMed ID: 22552217
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 7.